STM JOURNALS

Research & Reviews: A Journal of
Biotechnology

https://journals.stmjournals.com/rrjobt/

ISSN: 2231-3826 (Online)
ISSN: 2347-7245 (Print)
Volume 16, Issue 1, 2026
January–June
DOI (Journal): 10.37591/RRJoBT

Review RRJoBT

Engineering Anti-Tau Monoclonal Antibodies for Alzheimer's Disease and Parkinsonian Tauopathies: A Biotechnological Perspective

Kumar Monu[1], Soumili Majumdar[2,*], Zeya Fatima[1], Harsh Pandey[1]

Abstract

Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, are characterized by progressive neuronal loss associated with abnormal protein aggregation. Among these, tauopathies are defined by the accumulation of hyperphosphorylated tau protein, which plays a central role in disease progression. Advances in biotechnology have enabled the development of anti-tau monoclonal antibodies (mAbs) as promising therapeutic agents aimed at neutralizing pathological tau species and inhibiting their propagation. This review provides a comprehensive analysis of the biotechnological strategies underlying antibody engineering, production platforms, mechanisms of action, and clinical translation. Despite promising preclinical outcomes, limitations, such as poor blood–brain barrier penetration and insufficient clinical efficacy, remain major challenges. Emerging approaches including bispecific antibodies, nanobodies, and gene therapy-based delivery systems are discussed as next-generation solutions. Anti-tau monoclonal antibodies (mAbs) represent a promising therapeutic approach for Alzheimer's disease and Parkinson's disease, targeting pathological tau to inhibit its spread and promote clearance. Advances in antibody engineering have improved specificity and safety; however, challenges, such as limited blood–brain barrier penetration and tau heterogeneity, hinder clinical success. Emerging strategies, including bispecific antibodies, nanobodies, and gene-based delivery systems, aim to enhance therapeutic efficacy. Overall, anti-tau mAbs hold significant potential as disease-modifying treatments in neurodegenerative disorders.

Keywords: Alzheimer's disease, Parkinson's disease, neurodegenerative disorders, monoclonal antibodies, anti tau mAb, (HEK293), CHO, A affinity chromatography and size-exclusion chromatography, coupled with rigorous analytical characterization using techniques like HPLC and mass spectrometry

INTRODUCTION

Neurodegenerative diseases represent an increasing global health burden, with Alzheimer's disease being the most prevalent cause of dementia and Parkinson's disease representing the leading movement disorder. While amyloid-β pathology has historically dominated therapeutic research in Alzheimer's disease, increasing evidence suggests that tau pathology is more strongly associated with neuronal dysfunction and cognitive decline. Tau protein aggregation is also implicated in atypical parkinsonian disorders such as progressive supranuclear disorder and primary disorder (Tauopathies) [1–3].

From a biotechnological point of view, tau represents an attractive therapeutic target due to its extracellular propagation and defined structural domains capable of antibody binding. The development of monoclonal antibodies targeting tau has been facilitated by advances in recombinant

***Author for Correspondence**
Soumili Majumdar
E-mail: soumilimajumdar52@gmail.com

[1]Student, M.Sc. in Biotechnology, Department of P.G. Studies and Research in Biological Science, Rani Durgawati Vishwadiyalaya, Jabalpur, Madhya Pradesh, India
[2]Student, M. Tech in Biotechnology, KIIT University, Bhubaneshwar, Odisha, India

Received Date: April 01, 2026
Accepted Date: April 01, 2026
Published Date: April 10, 2026

Citation: Kumar Monu, Soumili Majumdar, Zeya Fatima, Harsh Pandey. Engineering Anti-Tau Monoclonal Antibodies for Alzheimer's Disease and Parkinsonian Tauopathies: A Biotechnological Perspective. Research & Reviews: A Journal of Biotechnology. 2026; 16(1): 57–69p.

DNA technology, protein engineering, and large-scale biomanufacturing systems. Monoclonal antibodies (mAbs) are a prime example of personalized therapy made possible by advances in immunology, molecular biology, and biochemistry. For example, diseases, such as cancer, can be assessed for specific symptoms, such as hormone receptors in breast cancer, which can then be targeted by mAbs to provide tailored treatment. The earliest documented use of antibody therapy was in 1796 by Dr. Was done by Edward Jenner, when he used smallpox pustular fluid to induce immunity in the recipient. It was not until 1975 that the production of mAbs for human use was established by Drs. Kohler and Milstein. The concept of mAbs as therapeutic agents is based on immunogenicity, especially when the immune system encounters foreign antigens.

DISCOVERY OF ANTIBODIES

The discovery of antibodies represents a foundational advancement in immunology and biomedical science. Antibodies are Y-shaped immunoglobulin proteins produced by B lymphocytes that play a crucial role in adaptive immunity by specifically recognizing and neutralizing pathogens such as bacteria and viruses [4, 5].

In 1890, Emil von Behring and Shibasaburo Kitasato demonstrated the effectiveness of serum therapy in treating diphtheria, establishing the principle of humoral immunity [4, 5]. Subsequently, in 1897, Paul Ehrlich coined the term "antibody" and proposed the side-chain theory, which explained antigen–antibody specificity and interaction [6, 7].

A major breakthrough occurred in 1959 when Rodney Porter and Gerald Edelman independently elucidated the molecular structure of antibodies, revealing their characteristic Y-shaped configuration [7]. The development of enzyme-linked immunosorbent assay (ELISA) in 1971 by Eva Engvall and Peter Perlmann revolutionized antibody detection and quantification, enabling sensitive diagnostic applications [7].

Further advancing the field, Susumu Tonegawa demonstrated the genetic mechanism of antibody diversity through somatic recombination, explaining how a limited number of genes can generate a vast antibody repertoire [7]. These milestones collectively paved the way for the development of monoclonal antibody technologies and their widespread applications in modern medicine [6, 7].

DEVELOPMENT OF HYBRIDOMA TECHNOLOGY

A transformative milestone in antibody research was the introduction of hybridoma technology in 1975 by Georges Köhler and César Milstein [8]. This technique involves the fusion of antigen-specific B lymphocytes with immortal myeloma cells to generate hybrid cells known as hybridomas, which are capable of continuous proliferation and high-yield antibody production [8].

The process begins with immunization of a host animal (typically a mouse) with a specific antigen, followed by isolation of antibody-producing B cells. These cells are fused with myeloma cells using chemical agents such as polyethylene glycol and forming hybridomas. Selected hybridomas are screened and cultured to produce monoclonal antibodies with high specificity and uniformity [9].

Hybridoma technology revolutionized biotechnology by enabling the large-scale production of identical antibodies, facilitating applications in diagnostics, therapeutics, and research. These monoclonal antibodies serve as precise tools for detecting and quantifying biomolecules, significantly advancing immunological and biomedical investigations [10].

MILESTONES IN MONOCLONAL ANTIBODY RESEARCH

The development of hybridoma technology marked a turning point in monoclonal antibody research, enabling consistent production of highly specific antibodies [11–16]. Monoclonal antibodies generated through hybridoma technology exhibit uniform chemical and functional properties, making them indispensable in clinical and research settings [17].

These antibodies have found extensive applications in disease diagnostics, targeted therapies (e.g., cancer immunotherapy), and experimental biology. Their ability to bind specific antigens with high precision has enhanced biomolecular detection and contributed significantly to personalized medicine and targeted drug delivery systems (Figure 1) [18–20].



Figure 1. Depicting the contrast between a healthy and Alzheimer's brain [21].

Alzheimer's disease and *Parkinson's disease* are two major progressive neurodegenerative disorders that primarily affect the aging population, each characterized by distinct pathological and clinical features. Alzheimer's disease is defined as a chronic, progressive disorder marked by a

decline in memory, cognition, and behavior, associated with the accumulation of extracellular amyloid-β plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, leading to widespread neuronal loss, particularly in the hippocampus and cerebral cortex [5]. In contrast, Parkinson's disease is primarily a movement disorder resulting from the degeneration of dopaminergic neurons in the substantia nigra of the midbrain, leading to a deficiency of dopamine and manifesting clinically as bradykinesia, resting tremor, muscle rigidity, and postural instability; it is pathologically characterized by the presence of Lewy bodies composed mainly of α-synuclein [19]. Although both conditions share underlying mechanisms of protein misfolding and neurodegeneration, they differ significantly in their primary symptoms, affected brain regions, and molecular pathology (Figure 2) [22].



Figure 2. Depicting the Parkinsons disease effect [23].

MOLECULAR BASIS OF TAU PATHOLOGY

Tau is a microtubule-associated protein encoded by the MAPT gene and plays a critical role in maintaining neuronal cytoskeletal integrity. Under physiological conditions, tau stabilizes microtubules and regulates axonal transport. However, in pathological states, tau undergoes extensive post-translational modifications, including hyperphosphorylation, truncation, and conformational changes, leading to the formation of insoluble aggregates known as neurofibrillary tangles [1, 24].

The propagation of tau pathology occurs via a prion-like mechanism, wherein misfolded tau species act as seeds that induce aggregation in neighboring neurons [25–30]. This trans-synaptic spread is a key driver of disease progression and provides a mechanistic basis for targeting extracellular tau using antibody-based therapies.

The molecular pathology of tau protein represents a central mechanistic axis in neurodegenerative disorders, such as Alzheimer's disease and related Parkinsonian tauopathies, wherein the normally soluble and functionally essential microtubule-associated protein undergoes profound structural and biochemical alterations that culminate in neuronal dysfunction and degeneration. Under physiological conditions, tau plays a critical role in stabilizing microtubules, regulating axonal transport, and maintaining neuronal polarity through a finely tuned balance of phosphorylation and dephosphorylation events; however, in pathological states, tau becomes aberrantly modified through a spectrum of post-

translational modifications, most notably hyperphosphorylation at multiple serine and threonine residues, along with truncation, acetylation, and conformational rearrangements, which collectively diminish its affinity for microtubules and promote its detachment into the cytosol. This destabilization triggers a cascade of pathological events characterized by the misfolding of tau into β-sheet-rich structures, followed by its self-assembly into soluble oligomeric intermediates that are increasingly recognized as the most neurotoxic species, and eventually into insoluble paired helical filaments and neurofibrillary tangles that disrupt intracellular architecture and impair synaptic function. Compounding this intracellular pathology is the emerging paradigm of prion-like propagation, wherein misfolded tau species are released into the extracellular space and subsequently internalized by neighboring neurons, acting as seeds that template the misfolding and aggregation of native tau, thereby facilitating the progressive spread of pathology across anatomically and functionally connected brain regions. This mechanistic insight has provided a compelling rationale for the development of anti-tau monoclonal antibodies using advanced biotechnological platforms, including recombinant expression systems such as Chinese Hamster Ovary.

(CHO) and HEK293 cells, which enable the production of highly specific, humanized antibodies with optimized pharmacokinetic and pharmacodynamic profiles [7]. These engineered antibodies are designed to target distinct tau epitopes, including the N-terminal region implicated in extracellular propagation and the microtubule-binding repeat domain critical for aggregation, with further enhancements achieved through affinity maturation techniques, such as phage display and directed evolution, to improve binding specificity and strength. Additionally, Fc engineering strategies have been employed to modulate immune effector functions by enhancing interactions with Fcγ receptors on microglia, thereby promoting the phagocytic clearance of tau-antibody complexes while minimizing pro-inflammatory responses [16]. Mechanistically, anti-tau antibodies exert their therapeutic effects primarily in the extracellular compartment by sequestering pathogenic tau species, inhibiting their neuronal uptake, and preventing trans-synaptic spread, while also facilitating their clearance via microglial-mediated phagocytosis; however, a significant limitation remains the predominantly intracellular localization of tau aggregates, which restricts antibody accessibility and underscores the need for next-generation innovations, such as bispecific antibodies capable of crossing the blood–brain barrier via receptor-mediated transcytosis, nanobody-based constructs with enhanced tissue penetration, and gene therapy approaches utilizing viral vectors like adeno-associated virus for sustained in vivo antibody expression. From a bioprocess engineering perspective, the large-scale manufacturing of these biologics necessitates robust upstream and downstream processes, including optimized cell culture systems, bioreactor design, and purification strategies, such as Protein A affinity chromatography and size-exclusion chromatography, coupled with rigorous analytical characterization using techniques, like HPLC and mass spectrometry, to ensure product quality, stability, and regulatory compliance [31]. Despite substantial advances in antibody engineering and preclinical validation, clinical translation has been challenging, with several candidates demonstrating target engagement but limited efficacy in improving cognitive outcomes, largely due to factors such as insufficient blood–brain barrier penetration, heterogeneity of tau species, and late-stage intervention; therefore, future directions in this field are increasingly focused on integrating multidisciplinary approaches, including precision medicine guided by biomarker profiling, combination therapies targeting multiple pathological pathways, and the application of artificial intelligence and systems biology to refine therapeutic design, ultimately aiming to unlock the full potential of anti-tau immunotherapy in modifying disease progression [20].

BIOTECHNOLOGICAL DEVELOPMENT OF ANTI-TAU MONOCLONAL ANTIBODIES

The biotechnological development of anti-tau monoclonal antibodies (mAbs) has undergone a significant transformation from conventional hybridoma-based approaches to highly sophisticated recombinant, protein engineering, and synthetic biology-driven platforms, enabling the generation of next-generation biologics with enhanced specificity, affinity, and therapeutic functionality for neurodegenerative disorders such as Alzheimer's disease [32–35]. Early monoclonal antibody production relied on murine hybridoma technology, which, although effective for antigen-specific

antibody generation, posed limitations in terms of immunogenicity and scalability; these challenges have been largely overcome through the adoption of mammalian expression systems, particularly Chinese Hamster Ovary (CHO) cells and human embryonic kidney (HEK293) cells, which facilitate proper protein folding, post-translational modifications, and human-like glycosylation patterns essential for maintaining antibody stability, bioactivity, and reduced immunogenic responses in clinical applications [23]. Among these, CHO cells have emerged as the industry gold standard due to their robustness, adaptability to large-scale bioreactor systems, regulatory acceptance, and ability to produce high yields of recombinant antibodies with consistent quality attributes, thereby supporting commercial manufacturing requirements. A critical determinant of therapeutic efficacy in anti-tau antibody [31, 32] design lies in precise epitope targeting, as tau is a structurally dynamic and multifunctional protein with multiple domains contributing differently to its pathological behavior; antibodies directed against the N-terminal region primarily target extracellular tau species and are instrumental in blocking prion-like propagation between neurons, whereas those recognizing the mid-domain contribute to the neutralization of soluble tau intermediates, and antibodies targeting the microtubule-binding repeat (MTBR) domain – considered the core aggregation-prone region – are particularly effective in inhibiting fibrillization and disrupting the formation of neurotoxic aggregates. Complementing epitope selection, advanced antibody engineering strategies play a pivotal role in optimizing therapeutic performance, wherein affinity maturation techniques, such as phage display and directed evolution, are employed to refine antigen–antibody interactions, significantly improving binding kinetics (association and dissociation rates) and overall binding strength. Furthermore, antibody humanization through complementarity-determining region (CDR) grafting onto human immunoglobulin frameworks is essential to minimize immunogenicity while preserving antigen specificity, thereby enhancing clinical compatibility and safety profiles. In addition, Fc engineering has emerged as a powerful tool to modulate effector functions by altering interactions with Fc gamma (Fcγ) receptors expressed on immune cells, such as microglia, leading to enhanced antibody-dependent cellular phagocytosis (ADCP) of tau aggregates, prolonged serum half-life through neonatal Fc receptor (FcRn) engagement, and controlled immune activation that minimizes pro-inflammatory signaling within the central nervous system. Collectively, these integrated biotechnological advancements – from optimized expression systems and rational epitope targeting to precision antibody engineering – have substantially advanced the development of anti-tau monoclonal antibodies, positioning them as promising candidates for disease-modifying therapies while also highlighting the complexity of designing biologics capable of effectively targeting the multifaceted pathology of tau in neurodegenerative diseases (Figure 3) [36–40].



Figure 3. Depicting the biotechnological development of anti tau Monoclonal antibodies.

MECHANISMS OF ACTION OF ANTI-TAU MONOCLONAL ANTIBODIES

Anti-tau monoclonal antibodies (mAbs) exert their therapeutic effects predominantly through extracellular mechanisms by selectively targeting soluble and propagation-competent tau species implicated in the progression of neurodegenerative disorders such as Alzheimer's disease. A central pathological feature of tauopathies is the release of misfolded tau into the extracellular milieu, where it acts as a seeding agent capable of inducing conformational conversion and aggregation of native tau in neighboring neurons via a prion-like mechanism. Anti-tau antibodies are designed to recognize and bind these extracellular tau species with high specificity, thereby sterically hindering their interaction with neuronal surface receptors, such as heparan sulfate proteoglycans (HSPGs), which are implicated in tau internalization. By blocking this uptake pathway, antibodies effectively inhibit trans-synaptic transmission of tau pathology, thus slowing the spatial progression of neurodegeneration across interconnected neuronal networks [14].

In addition to preventing cellular uptake, antibody-bound tau complexes are subject to immune-mediated clearance mechanisms, primarily through engagement with Fc gamma (Fcγ) receptors expressed on microglial cells, the resident immune cells of the central nervous system. This interaction facilitates antibody-dependent cellular phagocytosis (ADCP), leading to the internalization and lysosomal degradation of tau-antibody complexes, thereby reducing the extracellular pool of pathogenic tau. Importantly, Fc engineering strategies can modulate this interaction to enhance phagocytic efficiency while minimizing excessive neuroinflammatory responses, which are often detrimental in chronic neurodegenerative conditions [28].

Beyond clearance, anti-tau antibodies have also been shown to influence the intrinsic aggregation dynamics of tau protein. By binding to specific epitopes involved in nucleation and elongation processes – particularly within the microtubule-binding repeat (MTBR) domain – these antibodies can interfere with tau–tau interactions, thereby inhibiting fibril formation and destabilizing pre-existing aggregates [41].

Furthermore, certain antibodies can neutralize oligomeric tau species, which are increasingly recognized as the most neurotoxic intermediates, thus mitigating their capacity to act as seeds for further aggregation. This inhibitory effect on seeding activity is critical in disrupting the self-propagating cycle of tau pathology [42–45].

Emerging evidence also suggests that some anti-tau antibodies may exert indirect intracellular effects despite their extracellular mode of action. For instance, by reducing extracellular tau burden, antibodies may decrease the overall influx of pathogenic tau into neurons, thereby limiting intracellular aggregation over time. Additionally, innovative antibody formats, such as cell-penetrating antibodies and nanobody-based constructs, are being explored to directly target intracellular tau aggregates, although these approaches are still in early stages of development [30].

Despite these multifaceted mechanisms, a significant limitation of conventional anti-tau immunotherapy remains the predominantly intracellular localization of tau pathology, particularly in the form of mature neurofibrillary tangles, which are largely inaccessible to circulating antibodies due to the restrictive nature of the neuronal plasma membrane and the blood–brain barrier [46].

This spatial constraint reduces the overall therapeutic impact and highlights the need for advanced delivery systems and engineered antibody formats capable of penetrating neuronal cells or enhancing central nervous system bioavailability. Collectively, while anti-tau monoclonal antibodies demonstrate promising mechanisms including inhibition of tau propagation, enhancement of microglial clearance, and modulation of aggregation kinetics, overcoming intracellular accessibility and optimizing target engagement remain critical challenges for achieving robust clinical efficacy (Figure 4) [47].



Figure 4. Mechanisms of action of Anti-tau monoclonal antibody.

Step-by-Step Mechanism (Flowchart)

Abnormal Tau Formation
↓
Tau Misfolding & Aggregation (Neurofibrillary Tangles)
↓
Release of Extracellular Tau
↓
Spread of Tau Between Neurons
↓
[Anti-Tau Monoclonal Antibodies Administered]
↓
Binding to Extracellular Tau
↓

↓	↓	↓
Block Tau Uptake by Neighbouring Neurons	Promote Microglial Clearance (Phagocytosis)	Neutralize Toxic Tau Species
↓	↓	↓
Reduced Tau Spread	Enhanced Removal of Tau	Reduced Neurotoxicity

↓
Slowing Disease Progression (e.g., Alzheimer's disease) [46].

BIOPROCESS ENGINEERING AND MANUFACTURING CONSIDERATIONS

The large-scale production of monoclonal antibodies requires robust bioprocess engineering strategies. Upstream processes involve the optimization of cell lines, culture conditions, and bioreactor

systems to maximize yield and product quality. CHO cells are widely used due to their ability to perform human-like post-translational modifications and scalability [6].

Downstream processing includes purification techniques, such as Protein A affinity chromatography, ion-exchange chromatography, and size-exclusion chromatography, to ensure high purity and stability. Analytical techniques, including high-performance liquid chromatography (HPLC) and mass spectrometry, are essential for quality control and characterization of antibody products. Downstream processing is essential for ensuring purity and involves multistep chromatographic purification strategies. Protein A affinity chromatography is widely employed as the primary capture step due to its high specificity for immunoglobulins, enabling efficient separation of antibodies from host cell proteins and other impurities. This is typically followed by ion-exchange and size-exclusion chromatography to remove aggregates, contaminants, and process-related impurities, ensuring high product quality and stability. Analytical techniques, such as high-performance liquid chromatography (HPLC) and mass spectrometry (LC–MS), are critical for monitoring product purity, detecting host cell proteins, and characterizing structural attributes such as glycosylation and post-translational modifications [23].

A key manufacturing consideration specific to anti-tau mAbs is the requirement for high specificity and affinity toward pathological tau epitopes, which necessitate rigorous validation during development and quality control stages. Variability in glycosylation and structural heterogeneity arising from production systems can significantly impact pharmacokinetics, immunogenicity, and therapeutic efficacy, requiring tight process control and robust analytical characterization. Furthermore, scalability from laboratory to industrial production must comply with Good Manufacturing Practice (GMP) standards, ensuring reproducibility, sterility, and regulatory approval [48–51].

Despite advances in manufacturing platforms, challenges remain, including maintaining consistent product across batches, minimizing host cell protein contamination, and optimizing cost-effective large-scale production. Additionally, for neurodegenerative indications, manufacturing must support modifications that enhance blood–brain barrier penetration and target engagement, which may involve advanced engineering strategies such as Fc modification or bispecific antibody design. Process optimization and regulatory compliance are critical for successful translation from laboratory-scale production to commercial manufacturing (Tables 1 & 2).

Table 1. Demonstrating the modern anti-tau monoclonal antibodies (mAbs).

Antibody	Target	Company	Status
Semorinemab	N-terminal tau	Genentech / Roche	Phase II/III.
Gosuranemab (BIIB092)	N-terminal tau	Biogen	Discontinued (lack of efficacy).
Tilavonemab (ABBV-8E12)	Extracellular tau	AbbVie	Discontinued.
Zagotenemab (LY3303560)	Misfolded tau	Eli Lilly	Phase II (terminated).
Bepranemab (UCB0107)	Mid-domain tau	UCB	Phase II.
JNJ-63733657	Phosphorylated tau	Johnson & Johnson	Phase II.
E2814	MTBR (microtubule binding region)	Eisai	Ongoing trials.

Note: These are investigational/clinical-stage therapies mainly targeting tau pathology in Alzheimer's disease: [36].
Key Anti-Tau mAbs

Table 2. Denotes key anti-tau monoclonal antibodies.

Antibody	Target	Developer	Status
Semorinemab	N-terminal tau	Genentech / Roche	Clinical trials (AD).
Bepranemab (UCB0107)	Mid-domain tau	UCB	Phase II (tauopathies like PSP).
JNJ-63733657	Phosphorylated tau	Johnson & Johnson	Early clinical stage.
Tilavonemab (ABBV-8E12)	Extracellular tau	AbbVie	Discontinued.
Gosuranemab (BIIB092)	N-terminal tau	Biogen	Discontinued.

Note: (Primarily developed for Alzheimer's disease but explored for PD-related conditions) [45].

In the context of Parkinson's disease, anti-tau monoclonal antibodies (mAbs) are proposed to exert their therapeutic effects primarily through targeting extracellular tau species that contribute to disease propagation and neurodegeneration. These antibodies selectively bind to pathological tau present in the extracellular space, thereby preventing its uptake by neighboring neurons and inhibiting the prion-like, neuron-to-neuron spread of tau pathology. Furthermore, the formation of antibody–tau complexes facilitate their recognition by microglial cells, promoting phagocytosis and subsequent clearance via lysosomal degradation pathways. Collectively, these mechanisms contribute to a reduction in the accumulation of toxic tau species, ultimately attenuating tau-mediated neurotoxicity and potentially slowing disease progression, particularly in cases where tau co-pathology is implicated in cognitive decline associated with Parkinson's disease [52–55].

Clinical Trials and Current Challenges in Neurodegenerative Diseases

Clinical trials for Alzheimer's disease and Parkinson's disease increasingly focus on disease-modifying therapies targeting key pathogenic proteins such as amyloid-β, tau, and α-synuclein; however, despite promising preclinical data and advancements in biomarker-guided patient selection, clinical outcomes have remained modest and inconsistent. Major challenges include limited blood–brain barrier permeability restricting therapeutic delivery, significant disease heterogeneity affecting treatment response, and late-stage diagnosis reducing efficacy. Additionally, the lack of reliable biomarkers for early detection and monitoring, along with high costs, long trial durations, and safety concerns, further complicate clinical translation. Addressing these limitations through improved drug delivery systems, early intervention strategies, and precision medicine approaches is critical for enhancing the success of future therapeutic development in neurodegenerative disorders [35].

CONCLUSION

The engineering of anti-tau monoclonal antibodies (mAbs) represents a highly sophisticated and evolving biotechnological strategy aimed at modifying the trajectory of tau-mediated neurodegeneration in disorders such as Alzheimer's disease and Parkinson's disease. By leveraging advances in antibody design, including epitope-specific targeting, Fc-engineering, and enhanced binding affinity, these biologics have demonstrated the capacity to selectively recognize pathological tau conformers, inhibit their prion-like propagation, and facilitate their clearance through microglia-mediated and intracellular degradation pathways [37]. Despite robust mechanistic rationale and compelling preclinical efficacy, the translational success of anti-tau mAbs has been constrained by critical challenges, notably limited blood–brain barrier permeability, suboptimal target engagement within the central nervous system, and the complex heterogeneity of tau species across disease stages and tauopathies [56].

From a biotechnological perspective, ongoing innovations – including bispecific antibody platforms, antibody fragments and nanobodies, Fc-modulation to enhance effector function, and gene therapy-based delivery systems – offer promising avenues to overcome these limitations and improve therapeutic bioavailability and precision. Furthermore, the integration of biomarker-driven patient stratification and advanced neuroimaging techniques is expected to refine clinical trial design and optimize therapeutic outcomes [39].

Collectively, monoclonal antibody therapeutics signify a paradigm shift toward mechanism-based, disease-modifying interventions in neurodegenerative medicine. While current clinical outcomes underscore the inherent complexity of targeting tau pathology, continued interdisciplinary advancements at the interface of biotechnology, neuroscience, and translational medicine are likely to enhance the efficacy and clinical applicability of anti-tau strategies. Ultimately, such approaches hold substantial promises for redefining the therapeutic landscape of tauopathies and advancing precision medicine in neurodegenerative diseases [57].

Future Prospects and Discussion

The engineering of anti-tau monoclonal antibodies (mAbs) maintains to adapt as a promising yet complex healing method for tauopathies, in particular Alzheimer's disorder and Parkinson's sickness. Regardless of sturdy mechanistic justification and encouraging preclinical statistics, medical translation

has discovered substantial challenges, necessitating a vital re-evaluation of modern-day procedures and the exploration of subsequent-generation innovations. (forty-two) a main dilemma of first-era anti-tau mAbs lies of their restrained penetration throughout the blood–brain barrier (BBB), resulting in subtherapeutic concentrations within the critical apprehensive machine. Future techniques are an increasing number of focused on enhancing CNS transport via receptor-mediated transcytosis (e.g., transferring receptor concentrated on), Fc-engineering, and the improvement of bispecific antibodies able to simultaneously attractive tau and BBB delivery mechanisms. In parallel, nanobodies, and antibody fragments are gaining attention due to their smaller length, improved tissue penetration, and ability for intracellular concentrated on, thereby addressing one of the fundamental barriers of traditional antibodies [58–60].

Some other vital attention is the heterogeneity of tau species, including differences in isoforms, post-translational adjustments, and conformational states throughout disorder degrees and among tauopathies. This complexity indicates that future therapeutic achievement may additionally rely on epitope-specific concentrated on the maximum pathogenic tau species, in particular those involved in seeding and propagation. Moreover, combination treatment options focused on both tau and different pathological proteins, such as α-synuclein or amyloid-β, may also provide synergistic advantages, specifically in problems with overlapping proteinopathies [61].

Advances in biomarker improvement, consisting of cerebrospinal fluid (CSF) tau species and tau-specific positron emission tomography (puppy) imaging, are expected to play a critical function in affected person stratification, early analysis, and tracking therapeutic reaction. Such precision remedy approaches will permit better alignment of therapeutic interventions with ailment level, potentially improving medical outcomes. From a translational perspective, opportunity delivery platforms which include gene therapy-based totally expression of anti-tau antibodies and vector-mediated passive immunization are emerging as innovative answers to achieve sustained therapeutic ranges even as lowering dosing frequency. Moreover, optimization of antibody effector functions to modulate microglial pastime without inducing neuroinflammation stays a vital region of research [62].

In conclusion, whilst current anti-tau monoclonal antibody remedies have yet to acquire definitive clinical success, ongoing improvements in antibody engineering, delivery technology, and ailment biology provide a strong foundation for future breakthroughs. A multidisciplinary method integrating biotechnology, neuroscience, and clinical research will be critical to conquer present boundaries and absolutely understand the potential of anti-tau immunotherapy as a disorder-modifying method in neurodegenerative issues [63].

REFERENCES

1. Avila J, Lucas JJ, Pérez M, Hernández F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84(2):361–84.
2. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795–804.
3. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795–804.
4. Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: Current status and prospects. Lancet Neurol. 2018.
5. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
6. Öztürk MM, Emgård J, García-Revilla J, Fernández-Calle R, Yang Y, Deierborg T, et al. The role of microglia in the prion-like transmission of protein aggregates in neurodegeneration. Brain Commun. 2025;7(2):fcaf087.
7. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: History and future. Curr Opin Pharmacol. 2012;12(5):615–22.
8. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535.

9. Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14(7):399–415.
10. Cummings J, Lee G, Nahed P, Kambar ME, Zhong K, Fonseca J, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8(1):e12295.
11. Demlova R, Valík D, Obermannova R, Zdražilová-Dubská L. The safety of therapeutic monoclonal antibodies. Physiol Res. 2016;65(Suppl 4):S455–S462.
12. Ding C, Wu Y, Chen X, Chen Y, Wu Z, Lin Z, et al. Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990–2019. Front Public Health. 2022;10:952161.
13. Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;9(7):a028035.
14. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11(3):155–9.
15. Ghasemi M, Brown RH Jr. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2018;8:a024125.
16. Goedert M. Tau protein and neurodegeneration. Semin Cell Dev Biol. 2004;15(1):45–9.
17. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314(5800):777–81.
18. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954–63.
19. Duarte-Jurado AP, Gopar-Cuevas Y, Saucedo-Cardenas O, Loera-Arias MD, Montes-de-Oca-Luna R, Garcia-Garcia A, et al. Antioxidant therapeutics in Parkinson's disease: Current challenges and opportunities. Antioxidants (Basel). 2021;10(3):453.
20. Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: The story so far. Nat Rev Neurol. 2016;12(1):15–27.
21. Jagaran K, Singh M. Nanomedicine for neurodegenerative disorders: Focus on Alzheimer's and Parkinson's diseases. Int J Mol Sci. 2021;22(16):9082.
22. Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100(8):3451–61.
23. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.
24. Kovacs GG. Concepts and classification of neurodegenerative diseases. In: Handb Clin Neurol. 2018;145:301–7.
25. Prasad EM, Hung SY. Current therapies in clinical trials of Parkinson's disease: A 2021 update. Pharmaceuticals (Basel). 2021;14(8):717.
26. Lee SH, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H, et al. Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep. 2016;16(6):1690–700.
27. Li D, Cho YK. High specificity of widely used phospho-tau antibodies validated using a quantitative whole-cell based assay. J Neurochem. 2020;152(1):122.
28. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.
29. Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol. 1998;8(11):425–7.
30. Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012;2(7):a006247.
31. Novak P, Kontsekova E, Zilka N, Novak M. Ten years of tau-targeted immunotherapy: The path walked and the roads ahead. Front Neurosci. 2018;12:798.
32. Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends Mol Med. 2015;21(6):394–402.
33. Posner J, Barrington P, Brier T, Datta-Mannan A. Monoclonal antibodies: Past, present and future. In: Handb Exp Pharmacol. 2019. p. 81–141.
34. Lopez CL, Tariot PN, Caputo A, Langbaum JB, Liu F, Riviere ME, et al. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimers Dement (N Y). 2019; 5:216–27.

35. Lee AY, Jahansooz JR, Guittu D, Suzuki R, Pak L, Ishikawa KM, et al. Barriers to Alzheimer disease clinical trial participation in a minority population. Cogn Behav Neurol. 2024;37(1):40–47. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10948321/.
36. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595–608.
37. Shepard HM, Phillips GL, Thanos CD, Feldmann M. Developments in therapy with monoclonal antibodies. Clin Med (Lond). 2017;17(3):220–32.
38. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609–22.
39. Tiller KE, Tessier PM. Advances in antibody design. Annu Rev Biomed Eng. 2015;17:191–216.
40. Uchikado H, DelleDonne A, Ahmed Z, Dickson DW. Lewy bodies in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2006;65:387–95.
41. Uversky VN. Dancing protein clouds: Intrinsically disordered proteins in the norm and pathology, part C. Academic Press; 2021.
42. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:5–21.
43. World Health Organization. Neurological disorders: public health challenges. Geneva: World Health Organization; 2006.
44. Checking your browser - reCAPTCHA. Nih.gov. 2026. Available from: https://pubmed.ncbi.nlm.nih.gov/36918389/.
45. McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, et al. Parkinson's disease drug therapies in the clinical trial pipeline: 2023 update. J Parkinsons Dis. 2023;13(4):427–39.
46. Kopil CM, Asis A, Campbell C, Chowdhury S, Dexter DT, Fargo KN, et al. A coalition to advance treatments for Parkinson's disease, dementia with Lewy bodies, and related disorders. J Parkinsons Dis. 2024;14(6):1105–14.
47. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis. 2008;15(2):157–68.
48. Murphy K, Weaver C. Janeway's immunobiology. 9th ed. New York: Garland Science; 2016.
49. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology.
50. Silverstein AM. A history of immunology. Academic Press; 2009.
51. Kindt, T.J., Goldsby, R.A. and Osborne, B.A. (2007) Kuby Immunology. W. H. Freeman and Co., New York. - References - Scientific Research Publishing. Scirp.org. 2026. Available from: https://www.scirp.org/reference/referencespapers?referenceid=1209714.
52. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7.
53. Harlow E, Lane D. A laboratory manual. New York: Cold Spring Harbor Laboratory; 1988.
54. Leenaars M, Hendriksen CFM. Critical steps in the production of polyclonal and monoclonal antibodies. ILAR J. 2005;46(3):269–79.
55. Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol. 2001;19(9):819–22.
56. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9(10):767–74.
57. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87.
58. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220–33.
59. Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs. 2021;13(1):1860476.
60. Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1.
61. Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. MAbs. 2016;8(7):1177–94.
62. Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317–27.
63. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345–52.

